Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
See detailOptiVal: Vers de nouveaux outils de gestion pour les éleveurs laitiers wallons, Prédire la réussite à l’insémination
Laloux, Laurent; Bastin, Catherine ULg; Glorieux, Géry et al

Poster (2008, January 23)

Detailed reference viewed: 6 (3 ULg)
Full Text
Peer Reviewed
See detailOptiView − A Powerful and Flexible Decision Tool Optimising Space Allocation in Shipyard Workshops
Caprace, Jean-David ULg; Bair, Frédéric ULg; Losseau, Nicolas ULg et al

in Conference on Computer Applications and Information Technology in the Maritime Industries (COMPIT) (2008, May)

This paper presents new developments to maximize the number of ship blocks and ship sections produced in various workshops of shipyards during a certain time window. The visualization tool OptiView® was ... [more ▼]

This paper presents new developments to maximize the number of ship blocks and ship sections produced in various workshops of shipyards during a certain time window. The visualization tool OptiView® was developed to support users to improve the space utilization and workshop productivity. The software is coupled with a heuristic optimisation solver. The paper describes the approach to the space allocation problem and gives three application examples. [less ▲]

Detailed reference viewed: 125 (36 ULg)
Full Text
See detailOptoacoustic specific detection of prostate cancer using functionalized gold nanorods
Fleron, Maximilien ULg; Schol, Daureen ULg; Greisch, Jean-François et al

Poster (2007, November 16)

A major challenge in prostate cancer oncology is to develop more accurate imaging assessments than those currently available. Indeed, an efficient imaging technique which significantly improves the ... [more ▼]

A major challenge in prostate cancer oncology is to develop more accurate imaging assessments than those currently available. Indeed, an efficient imaging technique which significantly improves the sensitivity and specificity of the diagnostic and predicting the cancer behaviour would be extremely valuable. This project intends to prove the concept of using optoacoustic imaging in combination with biologically functionalized nanoparticles as an integrated biosensor based system for the production of specific and sensitive data for accurate diagnosis of prostate cancer. This concept results on the use of contrast agents which transform an incident luminous energy into local heating inducing a pressure wave detectable by acoustic (echography). For the optoacoustic detection, the nanoparticles used must present a maximum of absorption in the optical transparency window of the human tissues in order to allow their and subsequently the tissue specific excitations while avoiding unwanted destructive energy transfers. According to these characteristics (energy transfer by thermoelastic reaction), rod-like gold nanoparticles (stick form) with a maximum of absorption towards 760 nm were produced by using a “bottom-up” approach with dynamic templates (surfactant). These nanoparticles are then coupled with an antibody directed against the cancerous cells to guarantee the specific detection of the particles. The development of the biosensor is firstly performed to target the Prostate Specific Membrane Antigen (PSMA), a transmembrane protein considered as a suitable biomarker for prostate cancer. Detection and localisation of PSMA on LNCaP fixed cell surface was performed by immunostainning on monolayer cell culture and on spheroid slices. Then, by backscattered electron (BSE) microscopy analysis and two-photon luminescence imaging, detection of nanoparticles on fixed and living cell surface shows the successful binding of the biosensor to the cells expressing PSMA. In prospect, the detection of the biosensor will be tested on spheroids, on human biopsies and finally on in vivo models (mouse xenograft models). [less ▲]

Detailed reference viewed: 28 (3 ULg)
Full Text
See detailOptoacoustic specific detection of prostate cancer using functionalized gold nanorods
Fleron, Maximilien ULg; Schol, Daureen ULg; Greisch, Jean-François et al

Poster (2007, October 10)

Detailed reference viewed: 8 (5 ULg)
Full Text
See detailOptoacoustic specific detection of prostate cancer using functionalized gold nanorods
Schol, Daureen ULg; Fleron, Maximilien ULg; Greisch, Jean-François et al

Poster (2008, March 12)

Detailed reference viewed: 15 (6 ULg)
Full Text
See detailOPTOPUS observations of Halley’s comet
Lund, G.; Surdej, Jean ULg

in The Messenger (1986), 43

The multiobject spectrograph OPTOPUS, for use at the 3.6-m ESO telescope with the CCD detector, is described, and preliminary results of spectra obtained in December 1985 of selected regions in the coma ... [more ▼]

The multiobject spectrograph OPTOPUS, for use at the 3.6-m ESO telescope with the CCD detector, is described, and preliminary results of spectra obtained in December 1985 of selected regions in the coma of Halley's comet are presented. The instrument's 54 separately cabled optical fibers, whose input ends are located in the focal plane by connectors plugged into drilled starplates, enable light to be guided from freely distributed points in a 33 arcmin zone of the Cassegrain focal plane, to a common slit. The spectra show the presence of a very faint continuum, due to the scattering of solar line photons in the inner region of the coma, on which is superimposed the bright emission bands of molecules such as CN, C2, C3, and NH2. The spectra also indicate that the brightness decrease of molecular bands as a function of the projected radial distance is not the same for different molecules. 3-3 (PDF) ESO [less ▲]

Detailed reference viewed: 9 (0 ULg)
Full Text
See detailOr bleu / Or noir
BALTHASAR, JEAN PIERRE; COLLIGNON, FABRICE; DE WIT, PIERRE et al

Article for general public (2005)

Au grand mécontentement général, le prix du pétrole augmente irrésistiblement. Malgré cela, notre société ne semble pas disposée à changer ses habitudes. [...] Ces mois de vacances ont été riches en ... [more ▼]

Au grand mécontentement général, le prix du pétrole augmente irrésistiblement. Malgré cela, notre société ne semble pas disposée à changer ses habitudes. [...] Ces mois de vacances ont été riches en catastrophes climatiques. Ainsi, en Afrique de l'Ouest, des milliers de personnes ont disparu suite à une longue famine consécutive à un ciel resté trop longtemps avare en précipitations. En Méditerranée occidentale, on ne compte plus les milliers d'hectares de forêt partis en fumée à cause de la sécheresse. Au même moment, l'Europe centrale et orientale est lasse de patauger dans l'eau. Les spécialistes qualifient ces inondations comme étant les plus graves qu'aient connues la Suisse et la Roumanie. L'Inde est également noyée alors que Taïwan se prépare à la tempête la plus violente de son histoire. Et après ces préliminaires dramatiques, voici Katrina qui sème chaos et désolation. [...] [less ▲]

Detailed reference viewed: 61 (8 ULg)
Full Text
Peer Reviewed
See detailL’oracle et le messager. Fiction de l’interview chez Mallarmé
Durand, Pascal ULg

in Lieux Littéraires / La Revue (2006), 9/10

Detailed reference viewed: 26 (12 ULg)
Full Text
Peer Reviewed
See detailUn oracle médical de Sarpédon à Séleucie du Calycadnos
Nissen, Cécile ULg

in Kernos : Revue Internationale et Pluridisciplinaire de Religion Grecque (2001), 14

Detailed reference viewed: 21 (1 ULg)
Full Text
See detailOraison funèbre d'Alphonse Delescluse
Kurth, Godefroid ULg

Article for general public (1903)

Detailed reference viewed: 17 (1 ULg)
Full Text
See detailOraison funèbre de Dominique Keiffer
Kurth, Godefroid ULg

in Revue de l'Instruction Publique en Belgique (1902), XLV

Detailed reference viewed: 14 (0 ULg)
Peer Reviewed
See detailOral Abstract session: Stress echo in clinical practice: Friday 5 December 2014, 08:30-10:00Location: Agora.
Magne, J.; Donal, E.; Dulgheru, R. et al

Conference (2014, December)

Detailed reference viewed: 6 (0 ULg)
Full Text
Peer Reviewed
See detailOral administration of the growth hormone (GH) secretagogue NN703 in adult patients with GH deficiency.
Svensson, J.; Monson, J. P.; Vetter, T. et al

in Clinical Endocrinology (2003), 58(5), 572-580

OBJECTIVE: Little is known of the usefulness of GH secretagogues (GHSs) in GH-deficient (GHD) adults. The objective of this study was to determine the number of responders to treatment with NN703 in GHD ... [more ▼]

OBJECTIVE: Little is known of the usefulness of GH secretagogues (GHSs) in GH-deficient (GHD) adults. The objective of this study was to determine the number of responders to treatment with NN703 in GHD adults. DESIGN: A multicentre, randomized, double-blind, and placebo-controlled study. PATIENTS: Ninety-seven GHD adults were included. MEASUREMENTS: The GH response before and after 1 week of oral treatment with NN703 (n = 83) or placebo (n = 14) was determined. The first and last dose of NN703 was 3 mg/kg, whereas the dose of NN703 was 1.5 mg/kg/day during the 6 days between the first and last doses. Furthermore, all 97 patients received 1 micro g/kg GH-releasing hormone (GHRH) 3 weeks after the last dose of NN703. RESULTS: Serum GH peak and area under curve (AUC) values after the first NN703 administration were greater than those after placebo administration (P < 0.05). However, after correction for the lower body mass index (BMI) in the NN703 group, this difference lost statistical significance. After 1 week of therapy, GH peak and AUC values were similar following the final doses of NN703 and placebo. Serum peak and AUC values of other anterior pituitary hormones were similar between the NN703 and placebo groups both after the first and last administration of study drug. Nine of the 83 patients (11%) responded with a serum peak GH concentration >or= 5 micro g/l after the first and/or last NN703 administration, whereas no patient responded after placebo administration. Serum IGF-I was unaffected by 1-week NN703 treatment, whereas serum IGFBP-3 was increased (P < 0.05 vs. placebo) also after correction for BMI. Mean serum peak GH concentration after GHRH administration was 2.1 micro g/l (+/-0.3, SEM), which was higher than that after the first NN703 administration (1.32 +/- 0.3, P < 0.05). CONCLUSION: NN703 administration was generally well tolerated. Eleven per cent of the GHD adult patients responded with a peak GH response >or= 5 micro g/l after the first and/or last administration of oral NN703. Although a majority of GHD adults will not respond to NN703, the present results suggest that oral NN703 treatment could be useful in some adult patients with moderately severe GHD. These patients may be identified by a test dose of GHS. [less ▲]

Detailed reference viewed: 18 (0 ULg)
Peer Reviewed
See detailOral and inhaled corticosteroïds decreased eosinophilic airway inflammation and bronchial reactivity in ascaris suum-sensitized and challenged cats
Leemans, Jérôme ULg; Kirschvink, N.; Cambier, Carole ULg et al

in Proceedings: 26th Annual Symposium of the Veterinary and Comparative Respiratory Society (2008)

Detailed reference viewed: 28 (3 ULg)
Full Text
Peer Reviewed
See detailOral and intravenous ibandronate in the management of postmenopausal osteoporosis: A comprehensive review
Reginster, Jean-Yves ULg

in Current Pharmaceutical Design (2005), 11(28), 3711-3728

Convenient strategies are needed for postmenopausal osteoporosis management. Current oral bisphosphonates are effective and generally well tolerated, but are hampered by strict dosing requirements. Less ... [more ▼]

Convenient strategies are needed for postmenopausal osteoporosis management. Current oral bisphosphonates are effective and generally well tolerated, but are hampered by strict dosing requirements. Less frequent dosing schedules are expected to improve adherence to therapy and hence outcomes. Ibandronate is a potent, nitrogen-containing bisphosphonate in ongoing clinical development exploring its potential to be administered less frequently than at weekly intervals. Uniquely, ibandronate can be administered either orally or as an intravenous (i.v.) injection, with a between-dose interval of >2 months. In postmenopausal women, oral ibandronate, when administered either daily or intermittently, has demonstrated robust antifracture efficacy at the spine (62% [p=0.0001] and 50% [p=0.0006] risk reduction versus placebo), accompanied by significant increases in bone mineral density (BMD) at the spine and hip, and suppression of bone turnover markers. Studies of intermittent i.v. ibandronate injections in postmenopausal women have shown dose-related BMD gains and bone turnover marker suppression comparable to those obtained after a similar duration of treatment with the proven effective oral ibandronate regimen. Furthermore, in a trial conducted in patients with corticosteroid-induced osteoporosis, intermittent i.v. ibandronate injections reduced vertebral fracture risk by 62% versus an active control (p=0.043). In all these trials, the oral and i.v. ibandronate regimens were well tolerated. Ongoing, large multinational clinical trials are investigating two intermittent ibandronate regimens: once-monthly oral and intermittent i.v. injections. These simple ibandronate regimens are expected to provide the optimal combination of efficacy, tolerability and patient convenience, leading to improved treatment adherence and thus, enhanced outcomes in postmenopausal osteoporosis. [less ▲]

Detailed reference viewed: 12 (1 ULg)
Peer Reviewed
See detailOral antidiabetic agents. A guide to selection.
Scheen, André ULg; Lefebvre, Pierre ULg

in Drugs (1998), 55(2), 225-36

Type 2 diabetes mellitus (formerly named non-insulin-dependent diabetes mellitus or NIDDM) is a heterogeneous disease resulting from a dynamic interaction between defects in insulin secretion and insulin ... [more ▼]

Type 2 diabetes mellitus (formerly named non-insulin-dependent diabetes mellitus or NIDDM) is a heterogeneous disease resulting from a dynamic interaction between defects in insulin secretion and insulin action. Various pharmacological approaches can be used to improve glucose homeostasis via different modes of action: sulphonylureas essentially stimulate insulin secretion, biguanides (metformin) act by promoting glucose utilisation and reducing hepatic-glucose production, alpha-glucosidase inhibitors (acarbose) slow down carbohydrate absorption from the gut and thiazolidinediones (troglitazone) enhance cellular insulin action on glucose and lipid metabolism. These pharmacological treatments may be used individually for certain types of patients, or may be combined in a stepwise fashion to provide more ideal glycaemic control for most patients. Selection of oral antihyperglycaemic agents as first-line drug or combined therapy should be based on both the pharmacological properties of the compounds (efficacy and safety, profile) and the clinical characteristics of the patient (stage of disease, bodyweight, etc.). Mildly hyperglycaemic patients should preferably be treated with metformin, acarbose or thiazolidinediones (which are not associated with any hypoglycaemic risk), while more severely hyperglycaemic individuals should receive a sulphonylurea. In moderately hyperglycaemic patients, sulphonylureas should be preferred in nonobese patients while metformin, and probably also thiazolidinediones, should have priority in obese insulin-resistant type 2 diabetic patients. Acarbose is mainly indicated to reduce post-prandial glucose fluctuations and improve glycaemic stability. Each antihyperglycaemic agent may also be combined with insulin therapy to improve glycaemic control and/or reduce the insulin requirement of diabetic patients after secondary failure to oral treatment. Finally, safety should be taken into account in elderly patients and/or those with renal impairment, especially as far as the use of sulphonylureas (higher risk of hypoglycaemia) and metformin (higher risk of lactic acidosis) is concerned. [less ▲]

Detailed reference viewed: 24 (0 ULg)
Full Text
Peer Reviewed
See detailOral antifungal-exacerbated inflammatory flare-up reactions of dermatomycosis: Case reports and review of the literature
Nikkels, Arjen ULg; Tassoudji, Nazli ULg; Pierard, Gérald ULg

in American Journal of Clinical Dermatology (2006), 7(5), 327-331

Inflammatory flare-up reactions of some dermatomycoses, particularly those caused by zoophilic fungi, are typical and potentially severe adverse effects following the intake of some oral antifungals ... [more ▼]

Inflammatory flare-up reactions of some dermatomycoses, particularly those caused by zoophilic fungi, are typical and potentially severe adverse effects following the intake of some oral antifungals. However, this condition has not previously been reported with the most frequently used antifungals in dermatology, namely fluconazole, itraconazole, and terbinafine. In this report, we describe five patients, observed over a 10-year period, who presented with inflammatory exacerbations following oral antifungal therapy for dermatomycoses. We also review the literature on inflammatory reactions exacerbated by oral antifungal agents. Details of the patients' age, sex, occupation, and atopic background; the site of the lesion, its clinical and histologic features, and any systemic signs; the identity of the fungal pathogen; the antifungal agent taken by the patient; the time between drug intake and occurrence of the flare-up; the approach to management; and the outcome were documented for each patient. A PubMed literature search was also conducted, focusing on inflammatory exacerbations induced by griseofulvin, ketoconazole, itraconazole, fluconazole, and terbinafine. The patients were four farmers and one veterinarian (all male). All primary lesions were inflammatory dermatophytoses, including one kerion. Inflammatory exacerbation of the skin lesions started 12-24 hours after the intake of oral antifungals. Mild systemic changes, including slight fever and malaise, occurred in two cases. Itraconazole 400 mg/day was implicated as the causative agent in four cases and terbinafine 250 mg/day in one case. Mycologic cultures grew Trichophyton verrucosum in four cases. Antifungal treatment was discontinued in all patients. Oral and topical corticosteroids were administered to the two patients with systemic changes; the other three patients were treated with topical corticosteroids only. Two days after the onset of corticosteroids, lower doses of itraconazole (100 mg/day) and terbinafine (125 mg/day) were reintroduced. All lesions healed after 4-5 weeks. The PubMed search did not identify any articles that described inflammatory exacerbations of dermatomycoses induced by oral antifungals. Inflammatory flare-up of der-matomycoses is a rare but potentially severe cutaneous complication of oral antifungal use. Occupational contact with animals, inflammatory dermatomycoses, and zoophilic fungi represent common features in these patients. Although evidence-based data are not available, clinical experience shows that, in addition to antifungal therapy, topical and/or systemic corticosteroids are helpful to reduce the inflammatory reactions. The cases described in this article represent the first published report of oral antifungal-exacerbated inflammatory flare-up reactions of dermatomycosis in patients taking itraconazole or terbinafine. [less ▲]

Detailed reference viewed: 38 (3 ULg)
Full Text
Peer Reviewed
See detailOral antivirals revisited in the treatment of herpes zoster: what do they accomplish?
Nikkels, Arjen ULg; Pierard, Gérald ULg

in American Journal of Clinical Dermatology (2002), 3(9), 591-8

Oral antiviral agents currently represent the most important therapeutic keystone in the treatment of herpes zoster. Three oral antiviral agents are available for the treatment of herpes zoster: acyclovir ... [more ▼]

Oral antiviral agents currently represent the most important therapeutic keystone in the treatment of herpes zoster. Three oral antiviral agents are available for the treatment of herpes zoster: acyclovir, its derivative valacyclovir, and famciclovir. Meta-analysis of published data has shown that oral acyclovir significantly reduces various herpes zoster-related symptoms as well as the duration, intensity and prevalence of zoster-associated pain (ZAP). However, this drug does not influence postherpetic neuralgia. The newer agents famciclovir and valacyclovir exhibit a better oral bioavailability than acyclovir. These agents have demonstrated similar efficacy to acyclovir with ZAP and they require less frequent administration. When initiated within 72 hours, oral antiviral therapy of herpes zoster is beneficial in selected, elderly immunocompetent patients, reducing the duration and intensity of ZAP and providing more rapid skin lesion healing. Oral antivirals are also of benefit in immunocompromised patients with uncomplicated herpes zoster. However, signs of cutaneous and visceral dissemination should be monitored; if signs occur, intravenous antiviral therapy is indicated. [less ▲]

Detailed reference viewed: 25 (4 ULg)